Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| 07.03.2023 | Medical Ex... | medexcelca... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 16.02.2023 | Avilar Therapeutics Nabs $75M | WALTHAM, MA, Avilar Therapeutics increases financing round to $75 million. >> Click here fo... | vcnewsdail... |
| 16.02.2023 | Avilar Therapeutics Increases Seed Financing to $75M | Avilar Therapeutics, a Waltham, MA-based biopharmaceutical company focused on extracellular protein ... | finsmes.co... |
| - | Avilar Therapeutics | “We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a... | fastfounde... |